Genetic variability in susceptibility and response to toxicants

Toxicology Letters

Volumn 120, Issue 1-3, 2001, Pages 259-268

  Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Drug adducts; Genetic polymorphism; Genotyping; Idiosyncratic drug toxicity; Molecular epidemiology; Poor metabolisers; Ultrarapid metabolism

Indexed keywords

1,3 BUTADIENE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; CYTOCHROME P450 ISOENZYME; DICHLOBENIL; DIETHYLNITROSAMINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DISULFIRAM; FLUOROURACIL; HALOTHANE; ISOENZYME; LETROZOLE; LOSIGAMONE; METHOXYFLURANE; NICOTINE; QUINONE DERIVATIVE; VALPROIC ACID;

CANCER RISK; CONFERENCE PAPER; DRUG METABOLISM; DRUG RESPONSE; ENZYME INACTIVATION; ENZYME INDUCTION; ENZYME POLYMORPHISM; GENE AMPLIFICATION; GENE DUPLICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOSPITAL COST; HUMAN; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SIDE EFFECT; TOXICOKINETICS; XENOBIOTIC METABOLISM;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG THERAPY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASMS; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 0035977862     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(01)00278-8     Document Type: Conference Paper

References (35)

1. Acetone catabolism by cytochrome P450 2E1: Studies with CYP2E1-null mice
2. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas
3. Cloning and initial characterization of the human DPYD gene promoter
4. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes
5. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes
6. Drug related hospital admissions
7. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
8. Adverse drug reactions as a cause of admission to an acute medical assessment unit: A pilot study
9. Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases
10. CYP1A1 polymorphisms and lung cancer risk: A meta-analysis
11. Inherited variations in drug-metabolizing enzymes: Significance in clinical oncology
12. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
13. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
14. Pharmacogenetics of the alcohol dehydrogenase system
15. Reply
16. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
17. Genetic variation of CYP2A6, smoking, and risk of cancer
18. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes
19. Getting the right drug into the right patient
20. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity
21. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians
22. Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity
23. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity
24. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans
25. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: Implications for interindividual differences in nicotine metabolism
26. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function
27. Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism
28. Nicotine metabolism defect reduces smoking
29. Duplications and defects in the CYP2A6 gene: Identification, genotyping, and in vivo effects on smoking
30. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
31. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
32. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1
33. Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease